FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

General Information

Summary FT500 is an off-the-shelf, iPSC-derived NK cell product that can bridge innate and adaptive immunity, and has the potential to overcome multiple mechanisms of immune checkpoint inhibitor (ICI) resistance. The preclinical data provide compelling evidence supporting the clinical investigation of FT500 as monotherapy and in combination with ICI in subjects with advanced solid tumors.
Clinical trials phase Phase 1
Start date (estimated) 2019-02-15
End date (estimated) 2022-06-30

Administrative Information

NCT Number NCT03841110
Other study identifiers
Name FT500-101
Source weblink https://clinicaltrials.gov/ct2/show/NCT03841110
Regulatory body approval
Country
Public contact
Email clinical@fatetherapeutics.com
Public email clinical@fatetherapeutics.com
First name Peter
Last name Langecker
Phone +1 (0)858-875-1800
Country
United States
Sponsors Fate Therapeutics

Cell Line

Recruitment

Recruitment Status Recruiting
Estimated number of participants 64